|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Extended fault-location formulation for power distribution systems显示文摘 | Salim R H Resener M Filomena A D | 2009 | Power Delivery IEEE Trans on Industrial Electronics2009，24，2： | 1 |
| 2 | Hybrid fault diagnosis scheme implementation for power distribution systems automation显示文摘 | Salim R H de Oliveira K Filomena A D | 2008 | IEEE Trans on Power Delivery2008，23，4： | 1 |
| 3 | Hybrid fault diagnosis scheme implementation for power distribution systems automation显示文摘 | Filomena A D Salim R H de Oliveira K | 2008 | IEEE Trans on Power Delivery2008，23，4： | 1 |
| 4 | Hybrid fault diagnosis scheme implementation for power distribution systems automation显示文摘 | Salim R H de Oliveira K Filomena A D | 2008 | IEEE Trans on Power Delivery2008，23，4： | 1 |
| 5 | Evidence for oxidative actvation of c-myc-dependent nuclear signaling in human coronary smooth muscle cells and in early lesions of Watanabe heritable hyperlipidemic rabbits protective effects of vitamin E显示文摘 | Filomena D Tammam Y Silvia A | 2000 | Circulation2000，102，11： | 1 |
| 6 | Extended fault-location formulation for power distribution systems显示文摘 | SALIM R H RESENER M FILOMENA A D | 2009 | IEEE Trans on Power Delivery2009，24，2： | 1 |
| 7 | Extendedfault-location formulation for power distribution systems 显示文摘 | SALIM R H RESENER M FILOMENA A D | 2009 | IEEE Transactions on Power Delivery f2009，24，2： | 1 |
| 8 | Hybrid fault diagnosis scheme implementation for power distribution systems automation显示文摘 | Salim R H de Oliveira K Filomena A D | 2008 | IEEE Transactions on Power Delivery2008，23，4： | 1 |
| 9 | Advances in bacterial ex opolysaccharides: from production to bioteehnological application 显示文摘 | FILOMENA F VITOR D A MARIA A M R | 2011 | Trends Biotechnol2011，29，8： | 1 |
| 10 | Extended fault-location formulation for power distribution systems 显示文摘 | SAIAM R H RESENER M FILOMENA A D | 2009 | IEEE Transactions on Power Delivery2009，24，2： | 1 |
| 11 | Extended fault-location formulation for power distribution systems 显示文摘 | SALIM R H RESENER M FILOMENA A D | 2009 | IEEE Transactions on Power Delivery2009，24，2： | 1 |
| 12 | Polymorphism AGT2(rs4762)is involved in the development of dermatologic events:Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib显示文摘BACKGROUND Dermatologic adverse events(DAEs)are associated with a better outcome in patients with hepatocellular carcinoma(HCC)irrespective of the therapeutic agent received.The exact mechanisms associated with the development of DAEs are unknown although several studies point to direct toxicity of tyrosine kinase inhibitors(TKIs)to the skin or an immune-mediated reaction triggered by the oncologic treatment.As is the case in other conditions,individual genetic variants may partially explain a higher risk of DAEs.AIM To evaluate the contribution of several gene variants to the risk of developing DAEs in HCC patients treated with TKIs.METHODS We first analyzed 27 single-nucleotide polymorphisms(SNPs)from 12 genes selected as potential predictors of adverse event(AE)development in HCC patients treated with sorafenib[Barcelona Clinic Liver Cancer 1(BCLC1)cohort].Three additional cohorts were analyzed for AGT1(rs699)and AGT2(rs4762)polymorphisms-initially identified as predictors of DAEs:BCLC2(n=79),Northern Italy(n=221)and Naples(n=69)cohorts,respectively.The relation between SNPs and DAEs and death were assessed by univariate and multivariate Cox regression models,and presented with hazard ratios and their 95%confidence intervals(95%CI).RESULTS The BCLC1 cohort showed that patients with arterial hypertension(AHT)(HR=1.61;P value=0.007)and/or AGT SNPs had an increased risk of DAEs.Thereafter,AGT2(rs4762)AA genotype was found to be linked to a statistically significant increased probability of DAEs(HR=5.97;P value=0.0201,AA vs GG)in the Northern Italy cohort by multivariate analysis adjusted for BCLC stage,ECOG-PS,diabetes and AHT.The value of this genetic marker was externally validated in the cohort combining the BCLC1,BCLC2 and Naples cohorts[HR=3.12(95%CI:1.2-8.14),P value=0.0199,AGT2(rs4762)AA vs AG genotype and HR=2.73(95%CI:1.18-6.32)P value=0.0188,AGT2(rs4762)AA vs GG genotype].None of the other gene variants tested were found to be associated with the risk of DAE development.CONCLUSION DAE development in HCC patients receiving TKIs could be explained by the AGT2(rs4762)gene variant.If validated in other anti-oncogenic treatments,it might be considered a good prognosis marker. | Víctor Sapena Massimo Iavarone Loreto Boix Floriana Facchetti Maria Guarino Marco Sanduzzi Zamparelli Alessandro Granito Esther Samper Mario Scartozzi Josep Corominas Giorgia Marisi Alba Díaz Andrea Casadei-Gardini Laura Gramantieri Pietro Lampertico Filomena Morisco Ferran Torres Jordi Bruix María Reig | 2022 | World Journal of Hepatology2022，14，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员